NCT06408142 Universal Test and Connect for HIV Service Delivery in South Africa
| NCT ID | NCT06408142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Human Immunodeficiency Virus |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2026-01-19 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2026-01-19 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to determine how many patients with HIV or at high risk of getting HIV attend the Emergency Department (ED) in South Africa (SA). The investigators will integrate HIV assessment in the ED and see how many people who would be a candidate for a drug that prevents HIV (PrEP). Universal test and connect (UTC) is a strategy that universally tests all patients and connects patients to long-term care, whether HIV positive or negative, including referrals for PrEP. The investigator's goal is to use UTC across two busy 24-hr EDs in Cape Town, SA.
Eligibility Criteria
Inclusion Criteria for universal testing and connecting: * Patients attending the Emergency Department * Ages \> or = 12 years old in South Africa * For subset that participate in PrEP choice trial, inclusion criteria will be to ensure that they meet PrEP eligibility criteria and do not have any contraindications to PrEP (kidney disease, acute HIV signs or symptoms, already taking PrEP). Exclusion Criteria: * Patients unable to provide written informed consent - i.e., have a depressed level of consciousness (head trauma or concurrent alcohol/substance abuse), determined as critically ill (triage score of "emergent"), or * do not speak a language spoken by the study team (English, Afrikaans, and Xhosa). In-depth interviews and surveys to providers: Inclusion Criteria: * Nurses, physicians, or advanced practice providers (APPs) who work regularly in the Emergency Department at one of the clinical sites. * Consent to a recorded in-depth interview and/or Normalizing Process Theory (NPT) survey Exclusion Criteria: * Providers who have already been interviewed (if working at both clinical sites) * Providers who do not consent to an interview or a survey.
Contact & Investigator
Bhakti Hansoti, MD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT06408142 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Human Immunodeficiency Virus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06408142 currently recruiting?
Yes, NCT06408142 is actively recruiting participants. Contact the research team at drudolp3@jhmi.edu for enrollment information.
Where is the NCT06408142 trial being conducted?
This trial is being conducted at Cape Town, South Africa.
Who is sponsoring the NCT06408142 clinical trial?
NCT06408142 is sponsored by Johns Hopkins University. The principal investigator is Bhakti Hansoti, MD at Johns Hopkins University. The trial plans to enroll 2,000 participants.